Iksuda Therapeutics announces first patient dosed in Phase 1

Iksuda Therapeutics Iksuda the developer of class leading antibody drug conjugates ADCs with enhanced tumour specificity today announces that the first patient has completed a first cycle of therapy with IKS014 a human epidermal growth factor receptor 2 HER2 ADC targeting patients with advanced HER2 solid tumours.

Related Keywords

China , South Korea , Australia , Dave Simpson , Fosun Pharma , Legochem Biosciences , Iksuda Adcs , , Chief Executive Officer , Iksuda Therapeutics , Greater China , United Kingdom Based , Antibody Drug Conjugates , Media Contact , Iksuda Therapeutics Phase 1 Trial Iks014 Patients Solid Tumours Her2 Study Antibody Drug 2 Dose Conjugates Fosun Pharma Fs1502 1b Pharmacokinetics Pharmacodynamics Dr Dave Simpson Monomethyl Auristatinf Mmaf Hnstd Legochem Biosciences Breast Cancer Biotechnology Tumour Cancers Therapeutic Index ,